United Therapeutics reported first-quarter results above our and FactSet consensus expectations. Its treprostinil franchise for pulmonary arterial hypertension (PAH) remains fairly stable despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback